This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (4)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in JAMA  Topic Collections  • Substance Abuse/ Alcoholism  • Alert me on articles by topic  Social Bookmarking   What's this?

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: The study by Dr Garbutt and colleagues¹ demonstrates that the use of injectable naltrexone reduces the number of heavy drinking days in alcohol-dependent individuals. An important limitation in these results is that despite the long duration of the trial, the number of heavy drinking days per month did not progressively decrease over time, suggesting that longer treatment would be of no additional benefit. This is not surprising since craving, which is the strongest predictor of subsequent drinking and relapse,² has never been reported to be completely eliminated by naltrexone. Reduction of heavy drinking days has been previously established in randomized trials with the oral administration of the craving-reducing agents naltrexone,³ topiramate,⁴ and low-dose baclofen,⁵ and in an open-label trial of acamprosate.⁶

In validated animal models of craving for ethanol,⁷ only one of these medications, baclofen, which is a GABA(b) receptor agonist, has been shown at high dose . . . [Full Text of this Article]

Olivier Ameisen, MD
oameisen@noos.fr
Paris, France

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLES

Naltrexone Treatment for Alcohol Dependency—Reply
James C. Garbutt, Henry R. Kranzler, Stephanie S. O’Malley, David R. Gastfriend, Bernard L. Silverman, John W. Loewy, Elliot W. Ehrich, and Helen M. Pettinati
JAMA. 2005;294(8):900.
EXTRACT | FULL TEXT  

Efficacy and Tolerability of Long-Acting Injectable Naltrexone for Alcohol Dependence: A Randomized Controlled Trial
James C. Garbutt, Henry R. Kranzler, Stephanie S. O’Malley, David R. Gastfriend, Helen M. Pettinati, Bernard L. Silverman, John W. Loewy, Elliot W. Ehrich, and for the Vivitrex Study Group
JAMA. 2005;293(13):1617-1625.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

SUPPRESSION OF SYMPTOMS OF ALCOHOL DEPENDENCE AND CRAVING USING HIGH-DOSE BACLOFEN
BUCKNAM
Alcohol Alcohol 2007;42:158-160.
ABSTRACT | FULL TEXT